Oxsoralen-Ultra: profile and news

[an error occurred while processing this directive]

Other information

Indication
For the treatment of psoriasis and vitiligo

Pharmacology
Methoxsalen selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Methoxsalen-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.

Mechanism Of Action
after activationm it binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and function.

Drug Category
Antineoplastic Agents; Pigmenting Agents; ATC:D05AD02; ATC:D05BA02

Brand Names/Synonyms
Ammodin; Ammoidin; Meladinin; Meladinine; Meladoxen; Meloxine; Methoxa-Dome; Methoxalen; Methoxaten; Methoxsalen; New-Meladinin; Oxoralen; Oxsoralen; Oxsoralen Lotion; Oxsoralen-Ultra; Oxypsoralen; Proralone-Mop; Psoralen-Mop; Puvalen; Puvamet; Ultra Mop; Ultramop Lotion; Uvadex; Xanthotoxin; Xanthotoxine; Xanthoxin; Zanthotoxin

Dosage Forms
LIQUID

Absorption
Not Available

Interactions
Interactions for Methoxsalen: Concomitant Therapy Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.

Chemical IUPAC Name
Not Available

Chemical Formula
C12H8O4

Half Life
~2 hours.

Drug Type
Approved Drug

# Accession No
APRD00157

CAS Registry Number
298-81-7